€7.23
0.34% today
L&S, Jul 04, 10:39 pm CET
ISIN
US80706P1030
Symbol
SRRK
Sector
Industry

Scholar Rock Holding Corp. Stock price

$7.77
-1.71 18.04% 1M
-8.87 53.31% 6M
-11.03 58.67% YTD
+0.38 5.14% 1Y
-21.37 73.34% 3Y
-7.50 49.12% 5Y
-7.73 49.87% 10Y
Nasdaq, Closing price Wed, Jul 03 2024
+0.14 1.83%
ISIN
US80706P1030
Symbol
SRRK
Sector
Industry

Key metrics

Market capitalization $619.69m
Enterprise Value $441.39m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.39
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-189.21m
Free Cash Flow (TTM) Free Cash Flow $-152.02m
Cash position $238.43m
EPS (TTM) EPS $-2.20
P/E forward negative
Short interest 37.98%
Show more

Is Scholar Rock Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

Scholar Rock Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Scholar Rock Holding Corp. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Scholar Rock Holding Corp. forecast:

Buy
100%

Financial data from Scholar Rock Holding Corp.

Dec '23
+/-
%
Net Profit -166 -166
23% 23%
-
Depreciation and Amortization 2.84 2.84
71% 71%
-
Stock Compensation 27 27
2% 2%
-
Operating Cash Flow -145 -145
9% 9%
-
Investments 0.07 0.07
93% 93%
-
Dividend Paid - -
-
-
Free Cash Flow -145 -145
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Scholar Rock Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Scholar Rock Holding Corp. Stock News

Neutral
Business Wire
10 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, design...
Neutral
Business Wire
16 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 96,700 s...
Neutral
Business Wire
about one month ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhi...
More Scholar Rock Holding Corp. News

Company Profile

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Head office United States
CEO Jay Backstrom
Employees 150
Founded 2012
Website www.scholarrock.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today